Biorem Inc Stock Performance
| BRM Stock | CAD 2.53 0.04 1.56% |
The firm shows a Beta (market volatility) of 0.72, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioRem's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioRem is expected to be smaller as well. At this point, BioRem Inc has a negative expected return of -0.16%. Please make sure to confirm BioRem's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if BioRem Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days BioRem Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
Last Split Factor 1:4 | Last Split Date 2005-01-21 |
1 | Biorem Secures 13M in Orders, Bolstering Growth - TipRanks | 12/09/2024 |
2 | Is BioRem Using Too Much Debt - Simply Wall St | 02/13/2025 |
| Begin Period Cash Flow | 3.8 M |
BioRem |
BioRem Relative Risk vs. Return Landscape
If you would invest 293.00 in BioRem Inc on December 1, 2024 and sell it today you would lose (40.00) from holding BioRem Inc or give up 13.65% of portfolio value over 90 days. BioRem Inc is currently producing negative expected returns and takes up 4.0555% volatility of returns over 90 trading days. Put another way, 36% of traded stocks are less volatile than BioRem, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BioRem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioRem's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioRem Inc, and traders can use it to determine the average amount a BioRem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0396
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BRM |
Estimated Market Risk
| 4.06 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioRem is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioRem by adding BioRem to a well-diversified portfolio.
BioRem Fundamentals Growth
BioRem Stock prices reflect investors' perceptions of the future prospects and financial health of BioRem, and BioRem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioRem Stock performance.
| Return On Equity | 0.6 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 37.06 M | ||||
| Shares Outstanding | 15.8 M | ||||
| Price To Earning | 3.01 X | ||||
| Price To Book | 4.08 X | ||||
| Price To Sales | 0.99 X | ||||
| Revenue | 25.17 M | ||||
| Gross Profit | 6.24 M | ||||
| EBITDA | 3.47 M | ||||
| Net Income | 2.18 M | ||||
| Cash And Equivalents | 5.75 M | ||||
| Cash Per Share | 0.16 X | ||||
| Total Debt | 4.19 M | ||||
| Debt To Equity | 1.05 % | ||||
| Current Ratio | 2.24 X | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | 490.03 K | ||||
| Earnings Per Share | 0.29 X | ||||
| Market Capitalization | 46.45 M | ||||
| Total Asset | 24.08 M | ||||
| Retained Earnings | (1.92 M) | ||||
| Working Capital | 6.71 M | ||||
About BioRem Performance
Evaluating BioRem's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioRem has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioRem has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 20.85 | 24.39 | |
| Return On Tangible Assets | 0.08 | 0.09 | |
| Return On Capital Employed | 0.27 | 0.28 | |
| Return On Assets | 0.08 | 0.09 | |
| Return On Equity | 0.29 | 0.31 |
Things to note about BioRem Inc performance evaluation
Checking the ongoing alerts about BioRem for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioRem Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioRem Inc generated a negative expected return over the last 90 days | |
| BioRem Inc has high historical volatility and very poor performance | |
| BioRem Inc is unlikely to experience financial distress in the next 2 years | |
| Latest headline from news.google.com: Is BioRem Using Too Much Debt - Simply Wall St |
- Analyzing BioRem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioRem's stock is overvalued or undervalued compared to its peers.
- Examining BioRem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioRem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioRem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioRem's stock. These opinions can provide insight into BioRem's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioRem Stock Analysis
When running BioRem's price analysis, check to measure BioRem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRem is operating at the current time. Most of BioRem's value examination focuses on studying past and present price action to predict the probability of BioRem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRem's price. Additionally, you may evaluate how the addition of BioRem to your portfolios can decrease your overall portfolio volatility.